VVOS Vivos Therapeutics Inc

Price (delayed)

$0.1489

Market cap

$3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.9

Enterprise value

$13.73M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 12

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment solutions for breathing and sleep disorders arising from certain dentofacial abnormalities, including obstructive ...

Highlights
The gross profit has surged by 61% year-on-year and by 7% since the previous quarter
Vivos Therapeutics's revenue has increased by 45% YoY and by 7% from the previous quarter
VVOS's EPS is down by 13% YoY but it is up by 11% from the previous quarter
The equity has dropped by 183% year-on-year and by 173% since the previous quarter
The company's quick ratio has shrunk by 83% YoY and by 27% QoQ

Key stats

What are the main financial stats of VVOS

VVOS stock price

How has the Vivos Therapeutics stock price performed over time
Intraday
-4.92%
1 week
-7.57%
1 month
-49.87%
1 year
-95.57%
YTD
-92.67%
QTD
-67.24%

Financial performance

How have Vivos Therapeutics's revenue and profit performed over time
Revenue
$20.9M
Gross profit
$12.94M
Operating income
-$22.56M
Net income
-$25.46M
Gross margin
61.9%
Net margin
-121.8%
The net income has plunged by 78% YoY
The gross profit has surged by 61% year-on-year and by 7% since the previous quarter
Vivos Therapeutics's operating income has plunged by 58% YoY
Vivos Therapeutics's revenue has increased by 45% YoY and by 7% from the previous quarter

Price vs fundamentals

How does VVOS's price correlate with its fundamentals

Growth

What is Vivos Therapeutics's growth rate over time

Valuation

What is Vivos Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.66
VVOS's EPS is down by 13% YoY but it is up by 11% from the previous quarter
The equity has dropped by 183% year-on-year and by 173% since the previous quarter
VVOS's P/S is 91% below its 5-year quarterly average of 1.5 and 88% below its last 4 quarters average of 1.1
Vivos Therapeutics's revenue has increased by 45% YoY and by 7% from the previous quarter

Efficiency

How efficient is Vivos Therapeutics business performance
The return on invested capital has declined by 49% since the previous quarter and by 37% year-on-year
VVOS's ROS is down by 22% YoY but it is up by 4.6% from the previous quarter
The company's return on assets fell by 21% YoY and by 3.8% QoQ

Dividends

What is VVOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VVOS.

Financial health

How did Vivos Therapeutics financials performed over time
VVOS's total assets is 14% lower than its total liabilities
The company's quick ratio has shrunk by 83% YoY and by 27% QoQ
The current ratio has dropped by 80% year-on-year and by 22% since the previous quarter
The equity has dropped by 183% year-on-year and by 173% since the previous quarter
VVOS's debt to equity has surged by 63% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.